Pfizer Predicts Record Profits From COVID Products, Says Chances ‘Very High’ FDA Will Authorize Vaccine for Babies and Toddlers, by David Charbonneau, by David Charbonneau

Quick Hits: Bishops Violating Religious Freedom, the Media Narrative on Benedict XVI, by Phil Lawler 
February 10, 2022
The CCP’s Fake Democracy: How the CCP Controls China and Fools the World (Part I), by Chen Guangcheng
February 10, 2022

Pfizer announced Tuesday projected combined sales of its COVID vaccine and antiviral drug Paxlovid should top $54 billion in 2022, but the company’s stock dropped sharply today.


David Charbonneau, Ph.D.'s avatarPfizer announced Tuesday projected combined sales of its COVID vaccine and antiviral drug Paxlovid should top $54 billion in 2022, constituting more than 50% of the company’s expected revenues of about $100 billion.

The drugmaker predicted slightly lower 2022 revenues ($32 billion) for the vaccine compared to 2021, but increased revenues ($22 billion) from Paxlovid, the company’s COVID-19 pill.

Pfizer stock today “dropped sharply after the company’s 2022 sales guidance appeared to fall short of expectations,” Barron’s reported. …

Continue reading >>>>